JAMES LEE to Genotype
This is a "connection" page, showing publications JAMES LEE has written about Genotype.
Connection Strength
1.006
-
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention. Pharmacogenomics. 2024; 25(7):293-298.
Score: 0.563
-
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention. Am J Cardiol. 2023 09 01; 202:218-222.
Score: 0.132
-
Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response. Pharmacogenomics. 2020 12; 21(18):1271-1277.
Score: 0.110
-
Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. Pharmacogenomics. 2017 Jul; 18(11):1051-1057.
Score: 0.087
-
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention. Clin Pharmacol Ther. 2023 03; 113(3):615-623.
Score: 0.032
-
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. J Am Heart Assoc. 2022 02 15; 11(4):e024159.
Score: 0.030
-
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clin Pharmacol Ther. 2021 03; 109(3):705-715.
Score: 0.027
-
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med. 2019 10; 21(10):2255-2263.
Score: 0.025